A combination of amyloid PET and tau PET is a viable option for staging amyloidosis and tauopathy, but this approach seems unfeasible in real‐world clinical practice, in which dual PET scanning comes with substantial financial and logistic burden. The gene discussed is MAPT; the disease is tauopathy.